Anti-Amyloid-beta (Clone 6C3, MOAB-2)

Amyloid plaques composed primarily of the 42 amino acid form of amyloid-beta peptide (Abeta42) are a hallmark of Alzheimer's disease (AD). However, the roles of the various amyloid beta peptide(s), especially Abeta42, related to the neurotoxicity characteristic of AD remains unclear. A major hindrance to evaluating the role of Abeta in AD pathology has been the availability of anti-Abeta antibodies to selectively detect Abeta versus amyloid precursor protein (APP), Abeta40 versus Abeta42, and specific conformations of the peptide, particularly oligomeric forms. MOAB-2 (mouse IgG2b) is a pan-specific antibody specific to Abeta (residues 1-4) that differentiates intracellular Abeta from APP. MOAB-2 does not detect APP in cell culture media/lysates or in brain homogenates from transgenic mice expressing 5 familial AD mutation (5xFAD mice). Intraneuronal Abeta was confirmed by co-localization of MOAB-2 immunoreactivity with C-terminal antibodies specific for Abeta40 and Abeta42, and with cathepsin-D, a lysosomal marker. Additionally, MOAB-2 demonstrates strong intraneuronal and extra-cellular immunoreactivity in 5xFAD and 3xTg mouse brain tissues.Synonyms: Abeta. Immunogen: Oligomeric form of amyloid-beta peptide (Abeta42). Clone Designation: 6C3. Formulation: (Request formulation change), 200 µg of protein G-purified antibody. Storage Buffer: PBS, pH 7.2, with 50% glycerol, and 0.02% sodium azide. Host: Mouse. Isotype: IgG2b. Applications: ELISA, WB. Cross Reactivity: (+) Amyloid-beta, (+) Unaggregated, oligomeric, and fibrillar forms of synthetic Abeta42, (+) Unaggregated Abeta40, (-) APP. License: Sold under license from the University of Illinois. UniProt Accession #: P05067.